Disulfiram/Cu Kills and Sensitizes <i>BRAF</i>-Mutant Thyroid Cancer Cells to <i>BRAF</i> Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways

Disulfiram/Cu Kills and Sensitizes <i>BRAF</i>-Mutant Thyroid Cancer Cells to <i>BRAF</i> Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways

<i>BRAF<sup>V600E</sup></i>, the most common genetic alteration, has become a major therapeutic target in thyroid cancer. Vemurafenib (PLX4032), a specific inhibitor of <i>BRAF<sup>V600E</sup></i> kinase, exhibits antitumor activity in patients with &l...

Full description

Bibliographic Details
Main Authors: Jingyi Xie, Juan Liu, Man Zhao, Xinru Li, Yubo Wang, Yuelei Zhao, Hongxin Cao, Meiju Ji, Mingwei Chen, Peng Hou
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:International Journal of Molecular Sciences
Subjects:
thyroid cancer
disulfiram/Cu
<i>BRAF</i> kinase inhibitor
<i>HER3</i>
sensitizing effect
Online Access:https://www.mdpi.com/1422-0067/24/4/3418

Internet

https://www.mdpi.com/1422-0067/24/4/3418

Similar Items